Establishment of Tumor Organoids, Carcinoma-Associated Fibroblasts, and Counterpart Fibroblasts from the Same Esophageal Cancer Patient
April 3rd, 2026
This protocol describes a method for simultaneously isolating cancer organoids, carcinoma-associated fibroblasts (CAFs), and non-tumor-associated fibroblasts (CFs) from the same patient with esophageal squamous cell carcinoma (ESCC). Employment of these patient-matched materials could avoid issues from inter-patient variability and provide an appropriate experimental platform for ESCC research.
Overview
This article presents a protocol for the simultaneous isolation of cancer organoids, carcinoma-associated fibroblasts (CAFs), and counterpart fibroblasts (CFs) from the same esophageal squamous cell carcinoma (ESCC) patient. By establishing patient-matched cell types, the protocol aims to eliminate inter-patient variability, providing a robust platform for studying tumor-stromal interactions in ESCC.
Key Study Components
Area of Science
- Cancer biology
- Tumor microenvironment
- Cell culture techniques
Background
- ESCC is characterized by treatment resistance and frequent tumor recurrence.
- CAFs are important in modulating tumor progression and therapeutic response.
- Traditional studies often use long-term cultured, patient-mismatched cell lines, introducing variability.
- Inter-patient variability reduces reproducibility and reliability of experimental results.
Purpose of Study
- To develop a protocol for isolating cancer organoids, CAFs, and CFs from the same ESCC patient.
- To provide a patient-specific experimental platform for studying tumor-stromal interactions.
- To minimize inter-patient variability in ESCC research.
Methods Used
- Isolation of cancer organoids and CAFs from surgically resected ESCC tissue.
- Isolation of CFs from adjacent non-tumorous tissue as patient-specific controls.
- Three-dimensional culture of cancer organoids.
- Immunostaining for vimentin to confirm fibroblast identity.
Main Results
- Successful simultaneous isolation of cancer organoids, CAFs, and CFs from individual patients.
- Cancer organoids demonstrated robust growth in 3D culture conditions.
- Both CAFs and CFs stained positively for vimentin, confirming fibroblastic lineage enrichment.
- The protocol enables establishment of patient-matched experimental models.
Conclusions
- The described protocol effectively eliminates inter-patient variability in ESCC cell studies.
- It provides a valuable platform for investigating tumor-stromal interactions with improved reproducibility.
- This approach may enhance the reliability of preclinical ESCC research and therapeutic testing.
